Format

Send to

Choose Destination
J Allergy Clin Immunol. 2017 Feb;139(2):422-428.e4. doi: 10.1016/j.jaci.2016.04.056. Epub 2016 Jul 14.

Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.

Author information

1
University of Virginia Asthma and Allergic Diseases Center, Charlottesville, Va.
2
Indoor Biotechnologies, Charlottesville, Va.
3
University of Virginia Asthma and Allergic Diseases Center, Charlottesville, Va. Electronic address: tap2z@virginia.edu.

Abstract

We present results from clinical studies on plasma infusion done in the late 1970s in patients with hypogammaglobulinemia in which we documented the short half-life of both total and allergen-specific IgE in serum. The development of specific allergic sensitization in the skin of those patients followed by the gradual decrease in sensitization over 50 days was also documented. The data are included here along with a discussion of the existing literature about the half-life of IgE in both the circulation and skin. This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms that could explain the rapid removal of IgE from the circulation. These mechanisms have clinical implications that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease.

KEYWORDS:

IgE; Immunoglobulin; half-life; metabolism; omalizumab

PMID:
27496596
PMCID:
PMC5405770
DOI:
10.1016/j.jaci.2016.04.056
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center